Evidence map›Paper›PMID 37207275›Full record

ArticleiScience2023

Salivary gland cancer organoids are valid for preclinical genotype-oriented medical precision trials.

Tomohiko Ishikawa, Takenori Ogawa, Masahiro Shiihara, Hajime Usubuchi, Yuko Omori, Katsuya Hirose, Taito Itoh, Takuya Yoshida, Ayako Nakanome, Akira Okoshi and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Organoids in the oral and maxillofacial region: present and future.International journal of oral science · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Tomohiko IshikawaDepartment of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
Takenori OgawaDepartment of Otolaryngology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan.
Masahiro ShiiharaDepartment of Investigative Pathology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
Hajime UsubuchiDepartment of Pathology, Sendai Kousei Hospital, Sendai 980-0873, Japan.
Yuko OmoriDepartment of Investigative Pathology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
Katsuya HiroseDepartment of Investigative Pathology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
Taito ItohDepartment of Investigative Pathology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
Takuya YoshidaDepartment of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
Ayako NakanomeDepartment of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
Akira OkoshiDepartment of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
Kenjiro HigashiDepartment of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
Ryo IshiiDepartment of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
Masahiro RokugoDepartment of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
Shun WakamoriDepartment of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
Yasunobu OkamuraTohoku University Advanced Research Center for Innovations in Next-Generation Medicine, Sendai 980-8573, Japan.
Kengo KinoshitaTohoku University Advanced Research Center for Innovations in Next-Generation Medicine, Sendai 980-8573, Japan.
Yukio KatoriDepartment of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
Toru FurukawaDepartment of Investigative Pathology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
Tohoku University · JPGifu University · JPSendai Kousei Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Salivary gland cancers (SGCs) are heterogeneous tumors, and precision oncology represents a promising therapeutic approach; however, its impact on SGCs remains obscure. This study aimed to establish a translational model for testing molecular-targeted therapies by combining patient-derived organoids and genomic analyses of SGCs. We enrolled 29 patients, including 24 with SGCs and 5 with benign tumors. Resected tumors were subjected to organoid and monolayer cultures, as well as whole-exome sequencing. Organoid and monolayer cultures of SGCs were successfully established in 70.8% and 62.5% of cases, respectively. Organoids retained most histopathological and genetic profiles of their original tumors. In contrast, 40% of the monolayer-cultured cells did not harbor somatic mutations of their original tumors. The efficacy of molecular-targeted drugs tested on organoids depended on their oncogenic features. Organoids recapitulated the primary tumors and were useful for testing genotype-oriented molecular targeted therapy, which is valuable for precision medicine in patients with SGCs.

Indexed as

CancerCell biologyHealth sciencesStem cells research

Identifiers

PMID37207275
PMCPMC10189274
OpenAlexW4366525863

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.